Are radiopharmaceuticals safe? the case of FDG-18
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional do IEN |
Texto Completo: | http://carpedien.ien.gov.br:8080/handle/ien/1621 |
Resumo: | Too many false-positive and adverse reactions related to radiopharmaceuticals take place every day in hospitals routine, but many are not reported or even sensed. Information concerning these kind of reactions is not abundant and nuclear medicine staff is usually overwhelmed by this information. As every healthcare intervention carries some risk of harm, clinical decision making needs to be supported by a systematic assessment of the balance of benefit to harm. A systematic review that considers only the favorable outcomes of an intervention, without also assessing the adverse effects and false positives reactions, can mislead by introducing a bias favoring the intervention that in the case o radiopharmaceuticals may to render a important factor related not even to the quality of the drug but even to the quality of the diagnosis. The results suggest a logical framework to make decisions in reviews that incorporate false positive and adverse reactions. Also, was explored situations where a comprehensive investigation of false positive reactions and adverse effects was warranted and suggest strategies to identify practicable and clinically useful outcomes. We concluded that there is the necessity to include and to recognize how strategic choices made in the review process determine what harms are found, and how the findings may affect clinical decisions. Researchers undertaking a systematic review that incorporates false positive reaction and adverse reactions must understand the rationale for the suggested methods and be able to implement them in their review. Beyond a world effort should be made to report as many cases of false positive and adverse reactions with radiopharmaceuticals as possible. Only if this is done a complete picture of false positive reactions with radiopharmaceuticals can be drawn. |
id |
IEN_85f9e454060e16450507e3b2c5bbd9fe |
---|---|
oai_identifier_str |
oai:carpedien.ien.gov.br:ien/1621 |
network_acronym_str |
IEN |
network_name_str |
Repositório Institucional do IEN |
spelling |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon.SEQNRroliveira@ien.gov.brhttp://lattes.cnpq.br/2376670019296363ien2015-11-12T17:26:26Z2015-11-12T17:26:26Z2012SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. Are radiopharmaceuticals safe? the case of FDG-18.<strong>Adv Pharmacoepidem Drug Safety</strong>, California, v. 1, n.1, p. 1-5, 2012.http://carpedien.ien.gov.br:8080/handle/ien/1621Submitted by Jéssica Ramos (jessicafslr@yahoo.com.br) on 2015-11-12T17:26:26Z No. of bitstreams: 1 Are Radiopharmaceuticals Safe The Case of FDG-18.pdf: 1083829 bytes, checksum: e44be3a7db11e05b4e98d8c79072d911 (MD5)Made available in DSpace on 2015-11-12T17:26:26Z (GMT). No. of bitstreams: 1 Are Radiopharmaceuticals Safe The Case of FDG-18.pdf: 1083829 bytes, checksum: e44be3a7db11e05b4e98d8c79072d911 (MD5) Previous issue date: 2012Too many false-positive and adverse reactions related to radiopharmaceuticals take place every day in hospitals routine, but many are not reported or even sensed. Information concerning these kind of reactions is not abundant and nuclear medicine staff is usually overwhelmed by this information. As every healthcare intervention carries some risk of harm, clinical decision making needs to be supported by a systematic assessment of the balance of benefit to harm. A systematic review that considers only the favorable outcomes of an intervention, without also assessing the adverse effects and false positives reactions, can mislead by introducing a bias favoring the intervention that in the case o radiopharmaceuticals may to render a important factor related not even to the quality of the drug but even to the quality of the diagnosis. The results suggest a logical framework to make decisions in reviews that incorporate false positive and adverse reactions. Also, was explored situations where a comprehensive investigation of false positive reactions and adverse effects was warranted and suggest strategies to identify practicable and clinically useful outcomes. We concluded that there is the necessity to include and to recognize how strategic choices made in the review process determine what harms are found, and how the findings may affect clinical decisions. Researchers undertaking a systematic review that incorporates false positive reaction and adverse reactions must understand the rationale for the suggested methods and be able to implement them in their review. Beyond a world effort should be made to report as many cases of false positive and adverse reactions with radiopharmaceuticals as possible. Only if this is done a complete picture of false positive reactions with radiopharmaceuticals can be drawn.engInstituto de Engenharia NuclearIENBrasilRadiopharmaceuticalsSafetyNuclear MedicineOncologyRadiologyAre radiopharmaceuticals safe? the case of FDG-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlev. 1,p. 1-5.info:eu-repo/semantics/openAccessreponame:Repositório Institucional do IENinstname:Instituto de Engenharia Nuclearinstacron:IENLICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://carpedien.ien.gov.br:8080/xmlui/bitstream/ien/1621/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINALAre Radiopharmaceuticals Safe The Case of FDG-18.pdfAre Radiopharmaceuticals Safe The Case of FDG-18.pdfapplication/pdf1083829http://carpedien.ien.gov.br:8080/xmlui/bitstream/ien/1621/1/Are+Radiopharmaceuticals+Safe+The+Case+of+FDG-18.pdfe44be3a7db11e05b4e98d8c79072d911MD51ien/1621oai:carpedien.ien.gov.br:ien/16212015-11-13 10:03:41.336Dspace IENlsales@ien.gov.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 |
dc.title.pt_BR.fl_str_mv |
Are radiopharmaceuticals safe? the case of FDG-18 |
title |
Are radiopharmaceuticals safe? the case of FDG-18 |
spellingShingle |
Are radiopharmaceuticals safe? the case of FDG-18 SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. Radiopharmaceuticals Safety Nuclear Medicine Oncology Radiology |
title_short |
Are radiopharmaceuticals safe? the case of FDG-18 |
title_full |
Are radiopharmaceuticals safe? the case of FDG-18 |
title_fullStr |
Are radiopharmaceuticals safe? the case of FDG-18 |
title_full_unstemmed |
Are radiopharmaceuticals safe? the case of FDG-18 |
title_sort |
Are radiopharmaceuticals safe? the case of FDG-18 |
author |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. |
author_facet |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. SEQNR roliveira@ien.gov.br http://lattes.cnpq.br/2376670019296363 ien |
author_role |
author |
author2 |
SEQNR roliveira@ien.gov.br http://lattes.cnpq.br/2376670019296363 ien |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. SEQNR roliveira@ien.gov.br http://lattes.cnpq.br/2376670019296363 ien |
dc.subject.por.fl_str_mv |
Radiopharmaceuticals Safety Nuclear Medicine Oncology Radiology |
topic |
Radiopharmaceuticals Safety Nuclear Medicine Oncology Radiology |
dc.description.abstract.por.fl_txt_mv |
Too many false-positive and adverse reactions related to radiopharmaceuticals take place every day in hospitals routine, but many are not reported or even sensed. Information concerning these kind of reactions is not abundant and nuclear medicine staff is usually overwhelmed by this information. As every healthcare intervention carries some risk of harm, clinical decision making needs to be supported by a systematic assessment of the balance of benefit to harm. A systematic review that considers only the favorable outcomes of an intervention, without also assessing the adverse effects and false positives reactions, can mislead by introducing a bias favoring the intervention that in the case o radiopharmaceuticals may to render a important factor related not even to the quality of the drug but even to the quality of the diagnosis. The results suggest a logical framework to make decisions in reviews that incorporate false positive and adverse reactions. Also, was explored situations where a comprehensive investigation of false positive reactions and adverse effects was warranted and suggest strategies to identify practicable and clinically useful outcomes. We concluded that there is the necessity to include and to recognize how strategic choices made in the review process determine what harms are found, and how the findings may affect clinical decisions. Researchers undertaking a systematic review that incorporates false positive reaction and adverse reactions must understand the rationale for the suggested methods and be able to implement them in their review. Beyond a world effort should be made to report as many cases of false positive and adverse reactions with radiopharmaceuticals as possible. Only if this is done a complete picture of false positive reactions with radiopharmaceuticals can be drawn. |
description |
Too many false-positive and adverse reactions related to radiopharmaceuticals take place every day in hospitals routine, but many are not reported or even sensed. Information concerning these kind of reactions is not abundant and nuclear medicine staff is usually overwhelmed by this information. As every healthcare intervention carries some risk of harm, clinical decision making needs to be supported by a systematic assessment of the balance of benefit to harm. A systematic review that considers only the favorable outcomes of an intervention, without also assessing the adverse effects and false positives reactions, can mislead by introducing a bias favoring the intervention that in the case o radiopharmaceuticals may to render a important factor related not even to the quality of the drug but even to the quality of the diagnosis. The results suggest a logical framework to make decisions in reviews that incorporate false positive and adverse reactions. Also, was explored situations where a comprehensive investigation of false positive reactions and adverse effects was warranted and suggest strategies to identify practicable and clinically useful outcomes. We concluded that there is the necessity to include and to recognize how strategic choices made in the review process determine what harms are found, and how the findings may affect clinical decisions. Researchers undertaking a systematic review that incorporates false positive reaction and adverse reactions must understand the rationale for the suggested methods and be able to implement them in their review. Beyond a world effort should be made to report as many cases of false positive and adverse reactions with radiopharmaceuticals as possible. Only if this is done a complete picture of false positive reactions with radiopharmaceuticals can be drawn. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2015-11-12T17:26:26Z |
dc.date.available.fl_str_mv |
2015-11-12T17:26:26Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
status_str |
publishedVersion |
format |
article |
dc.identifier.citation.fl_str_mv |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. Are radiopharmaceuticals safe? the case of FDG-18.<strong>Adv Pharmacoepidem Drug Safety</strong>, California, v. 1, n.1, p. 1-5, 2012. |
dc.identifier.uri.fl_str_mv |
http://carpedien.ien.gov.br:8080/handle/ien/1621 |
identifier_str_mv |
SANTOS-OLIVEIRA, Ralph; FLEMING, Brandon. Are radiopharmaceuticals safe? the case of FDG-18.<strong>Adv Pharmacoepidem Drug Safety</strong>, California, v. 1, n.1, p. 1-5, 2012. |
url |
http://carpedien.ien.gov.br:8080/handle/ien/1621 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Instituto de Engenharia Nuclear |
dc.publisher.initials.fl_str_mv |
IEN |
dc.publisher.country.fl_str_mv |
Brasil |
publisher.none.fl_str_mv |
Instituto de Engenharia Nuclear |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional do IEN instname:Instituto de Engenharia Nuclear instacron:IEN |
reponame_str |
Repositório Institucional do IEN |
collection |
Repositório Institucional do IEN |
instname_str |
Instituto de Engenharia Nuclear |
instacron_str |
IEN |
institution |
IEN |
bitstream.url.fl_str_mv |
http://carpedien.ien.gov.br:8080/xmlui/bitstream/ien/1621/2/license.txt http://carpedien.ien.gov.br:8080/xmlui/bitstream/ien/1621/1/Are+Radiopharmaceuticals+Safe+The+Case+of+FDG-18.pdf |
bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 e44be3a7db11e05b4e98d8c79072d911 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Dspace IEN |
repository.mail.fl_str_mv |
lsales@ien.gov.br |
_version_ |
1656026985499983872 |